About 206A

Founded: 2006
Employees: n/a
CEO: Dai Takehara
WebsiteView website: prismbiolab.com

PRISM BioLab Co.,LTD engages in the research and development of pharmaceuticals using its proprietary drug discovery platform technology, PepMetics Technology. It develops E7386 targeting CBP/beta-catenin, which is in Phase II clinical trial for the treatment of cancer; and PRI724 targeting CBP/beta-catenin that is in Phase II clinical trial for treating cirrhosis. The company has a strategic collaboration with Receptor.AI Inc. for the development of an AI-integrated drug discovery platform. The company was founded in 2006 and is based in Fujisawa, treating Japan.

Recent 206A News & Updates

New Risk • Feb 15

New major risk - Revenue and earnings growth

Earnings have declined by 38% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (20% average weekly change). Earnings have declined by 38% per year over the past 5 years. Minor Risks Revenue is less than US$5m (JP¥684m revenue, or US$4.5m). Market cap is less than US$100m (JP¥7.09b market cap, or US$46.4m).

Recent updates

No updates

PRISM BioLab Co.,LTD Stock Price

206A Share Price Performance

206A Community Narratives

Trending Discussion

Recently Updated Narratives

Snowflake Analysis

PRISM BioLab Co.,LTD Key Details

About 206A

Recent 206A News & Updates

We Think PRISM BioLabLTD (TSE:206A) Can Afford To Drive Business Growth

Second quarter 2026 earnings released: JP¥8.59 loss per share (vs JP¥7.75 loss in 2Q 2025)

New major risk - Revenue and earnings growth

Recent updates

PRISM BioLab Co.,LTD Competitors

Otsuka Holdings

Daiichi Sankyo Company

Astellas Pharma

Shionogi